Related Experiment Video

Updated: Aug 30, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy?

Brigitte Lankat-Buttgereit1, Rüdiger Göke

  • 1Clinical Research Unit for Gastrointestinal Endocrinology, University of Marburg, 35037 Marburg, Germany. lankatbu@mailer.uni-marburg.de

Biology of the Cell
|November 25, 2003
PubMed

Insights

Program cell death protein 4 (Pdcd4) impacts apoptosis and suppresses cancer by inhibiting protein translation. This review covers Pdcd4

Area of Science:

  • Molecular biology
  • Cancer research
  • Cellular processes

Background:

  • Programmed cell death protein 4 (Pdcd4) is a novel gene.
  • Pdcd4 was first identified as a differentially expressed protein during apoptosis.
  • Pdcd4 has implications in transformation suppression via inhibition of protein translation.

Purpose of the Study:

  • To review the current knowledge on Pdcd4.
  • To summarize expression, structure, and function of Pdcd4.
  • To discuss the potential of Pdcd4 as a molecular target in cancer therapy.

Main Methods:

  • Literature review
  • Analysis of existing data on Pdcd4 expression
  • Review of studies on Pdcd4 structure and function

Main Results:

  • Pdcd4 plays a role in programmed cell death.
  • Pdcd4 inhibits protein translation, contributing to transformation suppression.
  • Pdcd4 exhibits potential as a molecular target for cancer therapy.

Conclusions:

  • Pdcd4 is a significant protein involved in apoptosis and cancer suppression.
  • Further research into Pdcd4's mechanisms could lead to novel cancer treatments.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.